Ana Rita Freitas

Dr. Ana Rita Freitas

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Ana Duarte MendesAna Duarte Mendes
Ana Duarte Mendes
AFAna Rita Freitas
Ana Rita Freitas
RVRodrigo Santos Vicente
Rodrigo Santos Vicente
MVMarina Vitorino
Marina Vitorino
MBMarta Vaz Batista
Marta Vaz Batista
SBSofia Braga
Sofia Braga
Ovarian cancer is one of the most common gynecological malignancies and has low survival rates. One of the main determinants of this unfavorable prognosis is the high rate of peritoneal metastasis at diagnosis, closely related to its morbidity and mortality. The mechanism underlying peritoneal carcinomatosis is not clearly defined, but a clear preference for omental spread has been described. Growing evidence suggests that adipose tissue plays a role in promoting cancer onset and progression. Moreover, obesity can lead to changes in the original functions of adipocytes, resulting in metabolic and inflammatory changes in the adipose tissue microenvironment, potentially increasing the risk of tumor growth. However, the specific roles of adipocytes in ovarian cancer have not yet been fully elucidated. Due to the undeniable link between obesity and cancer, the adipose tissue microenvironment could also present a promising therapeutic target that warrants further research. This review discusses the complex relationship between ovarian cancer and the adipose tissue microenvironment.

6 March 2025 in Cancers
Verified
Journal Article
Open access
PDF file
LGLisa Gonçalves
Lisa Gonçalves
HGHelena Guedes
Helena Guedes
Ana FortunaAna Fortuna
Ana Fortuna
TLTânia Lemos
Tânia Lemos
JGJoão Gramaça
João Gramaça
LCLuis Costa
Luis Costa
Background: Platinum-based chemotherapy (PBC) followed by avelumab maintenance is a treatment option for patients with advanced urothelial carcinoma (aUC) patients. However, the optimal treatment sequencing in the era of antibody–drug conjugates (ADCs) is yet to be determined. Recent studies suggest that the timing of immune checkpoint inhibitor (ICI) administration may impact patient outcomes, with a potential benefit from morning infusions. Methods: This retrospective study included 105 patients with aUC treated with avelumab in Portugal and intended to assess the safety and clinical outcomes (progression-free survival (PFS), overall survival (OS), and overall response rate (ORR)) and evaluate the impact of treatment timing (morning vs. afternoon) on patient outcomes. Results: The median follow-up from the start of avelumab was 17.7 months, the median PFS (mPFS) was 9.8 months (95% CI 4.9–14.7), and the median OS (mOS) was 39.5 months (95% CI 13.2–65.7). Immune-related adverse events (irAEs) were reported in 65.8% of patients, with 6.7% experiencing G3 irAEs. Among those who received a subsequent-line ADC upon disease progression (43%), the mOS from the start of avelumab was 23.1 months (95% CI 9.2–37.0). Multivariate analysis showed significant improvement in mOS with morning avelumab infusions (HR 0.35, 95% CI: 0.12–0.97, p = 0.042) and a trend towards improved mPFS (HR 0.43, 95% CI: 0.179–1.02, p = 0.055). Conclusions: This study confirms the clinical efficacy and safety of avelumab, showing improved outcomes over JAVELIN Bladder 100 and suggesting that morning infusions may offer a survival benefit in this context. Further research is needed to optimize treatment sequencing and explore the impact of infusion timing in ICI strategies.

9 January 2023 in Cureus
Verified
Journal Article
Open access
MVMarina Vitorino
Marina Vitorino
IEInês Eiriz
Inês Eiriz
TTTiago C. Tomás
Tiago C. Tomás
RVRodrigo Santos Vicente
Rodrigo Santos Vicente
Ana Duarte MendesAna Duarte Mendes
Ana Duarte Mendes
PNPaula Borralho Nunes
Paula Borralho Nunes
This article has been corrected at the request of the authors due to an error in the author order when originally published. The authors deeply regret that this error was not identified and corrected prior to publication. The correct author order is now shown.

28 September 2026 in Journal of Leukocyte Biology
Verified
Journal Article
Open access
TMT S C Martins
T S C Martins
RSR Salvador
R Salvador
BCB F Correia
B F Correia
DGD Grosa
D Grosa
MVM Vitorino
M Vitorino
MCM G Cabral
M G Cabral
Neutrophils, once viewed as short-lived and functionally uniform antimicrobial cells, are now recognized as highly plastic immune regulators with context-dependent roles in cancer. Among circulating neutrophil subsets, low-density neutrophils have emerged as a clinically relevant population in oncology due to their distinct phenotypic, potent immunosuppressive activity, and strong association with disease progression. Low-density neutrophils are rare in healthy individuals but markedly expanded in patients with solid tumors. Low-density neutrophils display enhanced activation, increased expression of immunoregulatory molecules such as programmed death-ligand 1, elevated reactive oxygen species production, and a heightened propensity for neutrophil extracellular trap formation, collectively impairing cytotoxic T cell function and promoting tumor immune evasion. Although low-density neutrophils have been described across multiple malignancies, their biological and clinical relevance has been most characterized in breast and lung cancers. This review synthesizes current knowledge on neutrophil biology, emphasizing the clinical and mechanistic features of low-density neutrophils, with a focus on these 2 tumor types. In breast cancer, increased low-density neutrophil abundance correlates with metastatic disease, poor response to neoadjuvant chemotherapy, immunosuppression, accelerated progression, and reduced survival. In lung cancer, elevated low-density neutrophil frequencies similarly associate with advanced disease stage, unfavorable clinical outcomes, and distinct surface marker profiles distinguishing them from high-density neutrophils. Mechanistic studies indicate that tumor-derived cytokines and chronic inflammation drive low-density neutrophil expansion, functional reprogramming, and tissue trafficking, linking systemic neutrophil dysregulation to advanced disease and metastatic progression. Finally, we highlight emerging biomarkers, unresolved challenges, and therapeutic strategies targeting neutrophil plasticity and low-density neutrophil-mediated immunosuppression, underscoring their potential as actionable components in precision oncology.